Day: June 17, 2025

BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States Study shows >95% success rate, validating BE-Smart for use with esophageal brush cytology. UNIONDALE, NY, June 17, 2025 (GLOBE NEWSWIRE) — ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced the successful completion of a key validation study evaluating the performance of the BE-Smart™ molecular diagnostic test compatibility with samples obtained from esophageal brush cytology. The study demonstrated BE-Smart™ achieved greater than a 95% technical success rate, confirming the BE-Smart’s ability to reliably and accurately detect our panel of biomarkers, designed to assess...

Expanded platform improves access, scales operations, and advances Incannex’s position in next-generation mental health treatment NEW YORK and MELBOURNE, Australia, June 17, 2025 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces entering into a 50:50 joint venture with Mind Medicine Australia (“MMA”) to operate a psychedelic-assisted therapies services clinic in Melbourne. Incannex CEO Joel Latham commented, “This joint venture is a significant milestone around our strategy to bring psychedelic-assisted therapies to those who need them most. Working alongside a leading organization in this space, we expect to build the clinical infrastructure necessary to deliver safe, effective,...

Represents Continuation of Long-Running Partnership Focused on Supporting Advancement of Novel Ophthalmic Therapeutic Toward Commercialization CHASKA, Minn., June 17, 2025 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a new 10-year commercial manufacturing and supply agreement with a key existing customer. This represents the latest agreement signed between the two companies to support the advancement of a novel ophthalmic therapeutic through clinical development and onto the market. “In outlining our growth strategy for the coming years, we have stressed the importance of our pipeline of late-stage customer projects that are nearing potential commercialization in the mid-term. The signing...

In alignment with the Presidential Executive Order “Unleashing American Drone Dominance” Golden, CO, June 17, 2025 (GLOBE NEWSWIRE) — TB2 Aerospace LLC, in collaboration with Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), a drone solutions, and systems developer, (NASDAQ: DPRO), is proud to announce the successful deployment and performance of the Drone Recharging Operational Payload System (DROPS) during the U.S. Army’s Sustainment Modernization Experiment 2025 (SMEX25). Throughout SMEX25’s week-long field exercises, the DROPS system, integrated with Draganfly’s Commander 3XL, achieved a 100% success rate in autonomously deploying, recovering, and recharging TB2’s tactical resupply pods. The event provided an opportunity to validate real-world operational performance in austere and high-demand...

– Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications – – CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase Inhibitor – ALPHARETTA, Ga., June 17, 2025 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the use of its SCS delivery platform will be featured in multiple presentations at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025 in Las Vegas, Nevada. Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development, commented, “Our proprietary SCS Microinjector® platform is an established,...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES WHITE ROCK, British Columbia, June 17, 2025 (GLOBE NEWSWIRE) — TDG Gold Corp (TSXV: TDG, OTCQX:TDGGF) (the “Company” or “TDG”) is pleased to announce that it has entered into an amalgamation agreement with Anyox Copper Ltd. (“Anyox”) which holds the former producing Anyox Copper project, located on the northwest coast of British Columbia, and a wholly-owned subsidiary of TDG (“Subco”), dated June 16, 2025 (the “Amalgamation Agreement”) pursuant to which the Company proposes to acquire all of the issued and outstanding securities of Anyox by way of a three-cornered amalgamation (the “Acquisition”) under the Business Corporations Act (British Columbia). In connection with the Acquisition, the Company is also pleased to announce that...

Highlights:Courvan Trend infill drilling results intersected near-surface gold zones with significant grades up to 6.2 g/t Au over 4.9 metres, including 26.8 g/t Au over 1.0 metres and thick gold zones, including an intersection of 3.1 g/t Au over 17.0 metres, including 14.1 g/t Au over 2.0 metres.The recently completed 50,000-metre winter infill drilling program was designed to support the upcoming 2025 Pre-Feasibility Study, which is expected by year-end.TORONTO, June 17, 2025 (GLOBE NEWSWIRE) — Probe Gold Inc. (TSX: PRB) (OTCQB: PROBF) (“Probe” or the “Company”), is pleased to provide the latest results from the Novador in-fill drill program on its 100%-owned Novador property (the “Property”) located near Val-d’Or, Quebec. The 50,000-metre winter infill drill program, initiated during the fall of 2024, was designed to...